Virology

Humanigen, NeuroRx Plan FDA Emergency Use Filings for COVID-19 Candidates

Mar 30, 2021 Genetic Engineering and Biotechnology News Two COVID-19 drug developers said they will seek emergency use authorizations (EUAs) from the FDA for their therapeutics following positive late-stage clinical results. Humanigen disclosed topline Phase III results showing that hospitalized patients who received lenzilumab and other treatments—including steroids and/or Gilead Sciences’ marketed drug Veklury® (remdesivir)—had a 54% greater […]